Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
213
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
Acquisition gains balance traffic headwinds.
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,900.50 | 3.00 | -0.03% |
| CAC 40 | 7,865.07 | 30.97 | 0.40% |
| DAX 40 | 25,449.19 | 194.98 | 0.77% |
| Dow JONES (US) | 51,521.28 | 253.38 | 0.49% |
| FTSE 100 | 10,541.69 | 43.75 | 0.42% |
| HKSE | 24,121.59 | 158.97 | -0.65% |
| NASDAQ | 27,599.79 | 122.48 | 0.45% |
| Nikkei 225 | 70,074.13 | 609.84 | -0.86% |
| NZX 50 Index | 13,692.84 | 7.28 | -0.05% |
| S&P 500 | 7,818.93 | 44.98 | 0.58% |
| S&P/ASX 200 | 8,734.10 | 1.60 | -0.02% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |